{"entity":{"id":"marcia-brose","kind":"person","name":"Marcia S. Brose","aka":[],"tldr":"Led DECISION, the trial that made sorafenib the first approved targeted drug for radioiodine-refractory thyroid cancer.","summary":"Marcia Brose was principal investigator of DECISION, the phase 3 trial that showed sorafenib doubles progression-free survival in radioiodine-refractory differentiated thyroid cancer and became the first targeted therapy approved for the disease in 40 years. She has led cabozantinib (COSMIC-311) and RET-inhibitor trials in thyroid cancer and chairs medical oncology at Jefferson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brose%20MS%5BAuthor%5D%20thyroid%20sorafenib%20OR%20cabozantinib"}],"tags":["thyroid","targeted-therapy"],"related":[],"cancers":["thyroid"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["jefferson-kimmel"],"pathways":[],"terms":[],"trials":["decision-sorafenib"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Medical Oncology, Sidney Kimmel Cancer Center at Jefferson Health","institutionId":"jefferson-kimmel","specialisms":["Thyroid cancer","Kinase inhibitors","Precision oncology","Head and neck cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brose%20MS%5BAuthor%5D%20thyroid%20sorafenib%20OR%20cabozantinib"}],"papers":[{"title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer (DECISION)","journal":"Lancet","year":2014,"doi":"10.1016/S0140-6736(14)60421-9"},{"title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00332-6"}]},"route":"/people/marcia-brose/","neighbours":{"cancer":[{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"institution":[{"id":"jefferson-kimmel","kind":"institution","name":"Sidney Kimmel Comprehensive Cancer Center at Jefferson Health","route":"/institutions/jefferson-kimmel/"}],"trial":[{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/"}]}}